COMMITTED TO HEALTHIER AGING
Klotho in the News
Klotho Therapeutics, Inc. Targets Kidney Disease with Series A Financing
Klotho protein shows great promise in the treatment of kidney disease, acute kidney injury and other diseases associated with aging
San Diego, CA, November 2, 2017 – Klotho Therapeutics, Inc. (KTI), a biotechnology company focused on commercializing its patent pending version of the protein/hormone Klotho, announced the first closing of a $10 million Series A Preferred round of financing to advance Klotho development for the highest priority indication: kidney disease. Thynk Capital (thynkcapital.com) led the investment. Proceeds of the financing will fund KTI’s manufacturing scale-up, first in-human studies and Investigational New Drug (IND) application with the FDA.
This round of funding builds upon the $100+ million invested in Klotho-related academic research that demonstrated Klotho’s positive impact not only on kidney function but also cognition, fibrosis, cancer and longevity. Klotho is found naturally in humans and animals. KTI has worldwide patents pending on versions of modified and recombinant Klotho that can be readily manufactured using standard cell culture technology.
The company’s funding announcement coincides with a scientific presentation by KTI key advisor Ming Chang Hu, MD, PhD, at the American Society of Nephrology 50th Annual “Kidney Week” held in New Orleans, LA from October 31 – November 5. Dr. Hu will speak to kidney professionals from around the world about the role of Klotho in AKI. According to Dr. Hu, “Acute Kidney Injury is a state of acute Klotho deficiency.” Dr. Hu’s presentation is on November 3, 2017 at 2pm CST in room 262 of the New Orleans Ernest N. Morial Convention Center.
“We believe Klotho protein has the potential to transform the treatment of AKI and be the first drug to slow the progression of chronic kidney disease that affects up to 40 million people in the US. This financing enables KTI to accelerate human trials and understand the therapeutic benefits of Klotho better,” said Jim Plante, KTI founder and CEO. “In addition, we are delighted to be working with Dr. Hu as he brings deep experience with Klotho and invaluable insight to our team.”
Klotho Therapeutics (KTI) is a biotechnology company developing a patent-pending Klotho protein that has great potential to delay diseases of aging and help people live well longer. Naturally occurring in humans and animals, Klotho positively influences longevity, cognition and kidney function as well as slowing progression of diabetes and cancer. KTI is led by successful biotech startup executives and operates virtually. For more information, please visit: www.klotho.com.
Contact: Lauren Essex
760 521 5900
KLOTHO Therapeutics Named One of San Diego Venture Group’s 2017 COOL Companies
Klotho Protein Found Naturally in Humans Offers a Road Map to Longevity, Biotech Company to Create Patent-pending Klotho.
San Diego, CA, June 5, 2017 – San Diego Venture Group (SDVG) honors KLOTHO Therapeutics, Inc. (KTI), one of the year’s most exciting start-ups, for its biotech innovation that could redefine society’s experience with aging. Klotho, a naturally occurring human protein discovered in 1997, has great potential to influence longevity, cognition and kidney function as well as slowing progression of diabetes and cancer. KTI has filed patents on modified Klotho proteins and plans to enter future human trials focused on one of many potential indications: kidney failure.
The name Klotho comes from the mythological Greek goddess Klotho, responsible for spinning the thread of life. It’s an appropriate name as Klotho protein is involved in many biological pathways with both human and animal data supporting its effects. For example, National Institutes of Health report Klothodeficient animals live 25% shorter and look older while animals overexpressing Klotho live 20-30% longer. Klotho also has the potential to delay major diseases of aging – kidney failure, Alzheimer’s, osteoporosis, cancer, hypertension and diabetes, according to published studies.
KLOTHO Therapeutics’ first focus is kidney failure, one of the major causes of death in the U.S. that affects up to 30 million people per year, 600,000 of whom are currently on dialysis. Today, there is no successful long-term therapy. KLOTHO founder/chairman Jim Plante has personal experience with kidney disease and is unwavering in his commitment to find a solution.
“Our work to help people live longer, healthier lives can have the same kind of societal impact that Jonas Salk had when he invented the polio vaccine in 1955,” said Jim Plante, a serial entrepreneur who manages a portfolio of twelve companies under Thynk Capital (thynkcapital.com). “Imagine if someone like me could have Klotho therapy to slow or even reverse kidney damage – and avoid dialysis. We have the potential to redefine longevity. That’s life-changing.”
Not only is KTI’s raison d’etre breaking new ground, but the way the company is handling development is as well. With no employees, KTI’s virtual business model redirects the 40% overhead a typical biotech spends to accelerate development and human trials, which the company is well positioned to begin in two years.
As part of the COOL awards, KTI is invited to be a part of SDVG’s Venture Summit on August 30, 2017, the largest annual gathering of VCs outside Silicon Valley.
About KLOTHO Therapeutics KLOTHO Therapeutics (KTI) is a biotechnology company developing a patent-pending Klotho protein that has great potential to delay diseases of aging and help people live well longer. Naturally occurring in humans and animals, Klotho positively influences longevity, cognition and kidney function as well as slowing progression of diabetes and cancer. KTI is a virtual company led by successful biotech startup executives, headquartered in San Diego, California. For more information, please visit: www.klotho.com.
Contact: Bill Ramage, firstname.lastname@example.org
Klotho Therapeutics Raises $10M to Test Drug in Kidney Disease
Xconomy San Diego —
Klotho Therapeutics, a virtual biotech developing a kidney disease treatment based on its proprietary engineered version of the human klotho enzyme, said Thursday it has raised $10 million in Series A financing from San Diego’s Thynk Capital.
Thynk Capital founder and principal Jim Plante also is Klotho’s founder and CEO. Plante is a technology industry veteran in San Diego who has served as the CEO of Bel-Tronics, and as the founding CEO of SmartDrive Systems and Pathway Genomics.
The klotho gene was identified in 1997, and encodes a protein that is produced primarily in the kidney. Studies in mice have shown that a defect in klotho expression can lead to a syndrome resembling aging, whereas the over-expression of klotho in mice can extend life. Such findings led scientists to name the gene after Clotho, one of the three fates in Greek mythology who spun the thread of life.
“What we’re doing is using recombinant technology to create molecules that are very similar to natural klotho,” Klotho’s chief development officer, Bill Rammage, told me Thursday. “The natural molecule has some limitations.”
“Although klotho was originally identified as a gene related to aging, about 80 percent of klotho is made in the kidneys, and we think that kidney disease is a more suitable initial target for a small biotech,” he added.
Chronic kidney disease affects approximately 14 percent of the U.S. population, according to the National Institute of Diabetes and Digestive and Kidney Diseases. The condition can progress to kidney failure, which requires patients to undergo dialysis or a kidney transplant to survive. Besides kidney disease, Klotho says its version of the protein could be used to treat diabetes, and even some cancers. Proceeds of the $10 million financing will be used to produce klotho in sufficient quantities for necessary pre-clinical and clinical studies.
In a statement Thursday, Klotho said it has worldwide patents pending on versions of modified and recombinant klotho that can be readily manufactured using standard cell culture technology.
The pre-clinical stage company said its funding announcement coincides with a scientific presentation by Ming Chang Hu, an associate professor at the University of Texas Southwestern Medical Center in Dallas, TX, at an American Society of Nephrology conference in New Orleans this week. According to Hu, a member of Klotho’s medical advisor board, “acute kidney injury is a state of acute klotho deficiency.”
The company’s statement quotes Plante as saying, “We believe klotho protein has the potential to transform the treatment of [acute kidney injury] and be the first drug to slow the progression of chronic kidney disease that affects up to 40 million people in the US.”